Literature DB >> 15149160

An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymphnode metastasis in breast cancer.

K Przybylowska1, J Zielinska, M Zadrozny, T Krawczyk, A Kulig, P Wozniak, J Rykala, A Kolacinska, Z Morawiec, J Drzewoski, J Blasiak.   

Abstract

A single guanine insertion (1G/2G polymorphism) in the promoter of the matrix metalloproteinase (MMP-1) gene creates a binding site for the transcription factor and may affect the level of transcription of MMP-1. An elevated level of MMP-1 in cancer cells may facilitate their invasion and contribute to metastasis. To evaluate the contribution of 1G/2G polymorphism in the development and/or progression of breast cancer we genotyped 135 subjects with breast cancer. The 1G/2G polymorphism was determined by the method based on restriction endonuclease digestion. We found that the frequency of the 2G allele was higher in lymphnode-metastasis patients than in the group without metastasis (p < 0.001). We did not find differences between distribution of the genotypes and frequencies of alleles in cancer patients and in healthy subjects served as control. Our results suggest that allele 2G may be associated with lymphnode metastasis in patients with breast cancer and therefore it can be considered as a prognostic marker in this disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15149160

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  8 in total

1.  Analysis of matrix metalloproteinase-1 gene polymorphisms and expression in benign and malignant breast tumors.

Authors:  Jing Zhou; Constance Brinckerhoff; Susan Lubert; Kui Yang; Jasmine Saini; Jeffrey Hooke; Richard Mural; Craig Shriver; Stella Somiari
Journal:  Cancer Invest       Date:  2011-11       Impact factor: 2.176

2.  Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element.

Authors:  Karl E Miletti-González; Kyle Murphy; Muthu N Kumaran; Abhilash K Ravindranath; Roman P Wernyj; Swayamjot Kaur; Gregory D Miles; Elaine Lim; Rigel Chan; Marina Chekmareva; Debra S Heller; David Foran; Wenjin Chen; Michael Reiss; Elisa V Bandera; Kathleen Scotto; Lorna Rodríguez-Rodríguez
Journal:  J Biol Chem       Date:  2012-03-20       Impact factor: 5.157

3.  What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us?

Authors:  Ferdinando Mannello
Journal:  BMC Med       Date:  2011-08-11       Impact factor: 8.775

4.  Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma.

Authors:  Li-E Wang; Yu-jing Huang; Ming Yin; Jeffrey E Gershenwald; Victor G Prieto; Jeffrey E Lee; Madeleine Duvic; Elizabeth A Grimm; Qingyi Wei
Journal:  Eur J Cancer       Date:  2010-07-23       Impact factor: 9.162

Review 5.  Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer metastasis and chemotherapeutic drug-induced apoptosis.

Authors:  Cheng-Jeng Tai; Chung-Huei Hsu; Shing-Chuan Shen; Woan-Ruoh Lee; Ming-Chung Jiang
Journal:  J Exp Clin Cancer Res       Date:  2010-08-11

6.  Matrix metalloproteinase-1 (MMP-1) Promoter polymorphisms are well linked with lower stomach tumor formation in eastern Indian population.

Authors:  Sanjib Dey; Nillu Ghosh; Debjit Saha; Kousik Kesh; Arnab Gupta; Snehasikta Swarnakar
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

Review 7.  Matrix metalloproteinases and genetic mouse models in cancer research: a mini-review.

Authors:  Edyta Wieczorek; Ewa Jablonska; Wojciech Wasowicz; Edyta Reszka
Journal:  Tumour Biol       Date:  2014-10-29

8.  Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer.

Authors:  Chiranjeevi Padala; Mohini Aiyengar Tupurani; Kaushik Puranam; Srilatha Gantala; Nivas Shyamala; Mrudula Spurthi Kondapalli; Kishore Kumar Gundapaneni; Saraswati Mudigonda; Rajesh Kumar Galimudi; Keerthi Kupsal; Santoshi Rani Nanchari; Uday Chavan; Sanjeeva Kumari Chinta; Srinivasulu Mukta; Vishnupriya Satti; Surekha Rani Hanumanth
Journal:  PLoS One       Date:  2017-09-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.